| Transfusion Support of Patients with Myelodysplastic Syndromes |
|
Clinics in Laboratory Medicine |
Myelodysplastic Syndromes (MDS) |
| Traipsing Through Muddy Waters: A Critical Review of the Myelodysplastic Syndrome/Myeloproliferative Neoplasm (MDS/MPN) Overlap Syndromes |
|
Hematology/oncology clinics of North America |
Myelodysplastic Syndromes (MDS), Myeloproliferative Neoplasms (MPN) |
| TP53 mutations in myelodysplastic syndromes and secondary AML confer an immunosuppressive phenotype |
|
Blood |
Acute Myeloid Leukemia (AML), Myelodysplastic Syndromes (MDS) |
| TP53 mutation status divides myelodysplastic syndromes with complex karyotypes into distinct prognostic subgroups. |
|
Leukemia |
Myelodysplastic Syndromes (MDS) |
| Towards graft- versus-host disease-free alternative donor transplant platforms for patients with acquired aplastic anemia |
|
Haematologica |
Aplastic Anemia, Graft Versus Host Disease (GVHD) |
| Towards a Conceptualization of Measurable Residual Disease in Myelodysplastic Syndromes |
|
Blood Advances |
Myelodysplastic Syndromes (MDS) |
| Toward a more patient-centered drug development process in clinical trials for patients with myelodysplastic syndromes/neoplasms (MDS): Practical considerations from the International Consortium for MDS (icMDS) |
|
HemaSphere |
Myelodysplastic Syndromes (MDS) |
| To Target the Untargetable: Elucidation of Synergy of APR-246 and Azacitidine in TP53 Mutant Myelodysplastic Syndromes and Acute Myeloid Leukemia |
|
Haematologica |
Acute Myeloid Leukemia (AML), Myelodysplastic Syndromes (MDS) |
| Time without transfusion reliance: a novel patient-centric metric for new therapies in myelodysplastic syndromes |
|
Haematologica |
Myelodysplastic Syndromes (MDS) |
| Thrombosis in Paroxysmal Nocturnal Hemoglobinuria (PNH): From Pathogenesis to Treatment |
|
International Journal of Molecular Sciences |
Paroxysmal Nocturnal Hemoglobinuria (PNH) |
